Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Braz. j. med. biol. res ; 51(6): e7238, 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-889106

RESUMEN

Ulomoides dermestoides is a beetle traditionally consumed to treat diabetes. In this study, we performed a composition analysis of U. dermestoides to obtain the principal fractions, which were used to assess the effect on glycemia, liver and pancreatic architecture, and PPARγ and GLUT4 expression. Normal mice and alloxan-induced diabetic mice were administered fractions of chitin, protein or fat, and the acute hypoglycemic effect was evaluated. A subacute study involving daily administration of these fractions to diabetic mice was also performed over 30 days, after which the liver and pancreas were processed by conventional histological techniques and stained with hematoxylin and eosin to evaluate morphological changes. The most active fraction, the fat fraction, was analyzed by gas chromatography-mass spectrometry (GC-MS), and PPARγ and GLUT4 mRNA expressions were determined in 3T3-L1 adipocytes. The protein and fat fractions exhibited hypoglycemic effects in the acute as well as in the 30-day study. Only the fat fraction led to elevated insulin levels and reduced glycemia, as well as lower intake of water and food. In the liver, we observed recovery of close hepatic cords in the central lobule vein following treatment with the fat fraction, while in the pancreas there was an increased density and percentage of islets and number of cells per islet, suggesting cellular regeneration. The GC-MS analysis of fat revealed three fatty acids as the major components. Finally, increased expression of PPARγ and GLUT4 was observed in 3T3-L1 adipocytes, indicating an antidiabetic effect.


Asunto(s)
Animales , Masculino , Páncreas/efectos de los fármacos , Extractos de Tejidos/uso terapéutico , Escarabajos/química , Cuerpo Adiposo/química , Hipoglucemiantes/uso terapéutico , Hígado/efectos de los fármacos , Páncreas/metabolismo , Páncreas/patología , Extractos de Tejidos/aislamiento & purificación , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Regulación de la Expresión Génica , PPAR gamma/efectos de los fármacos , PPAR gamma/metabolismo , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/tratamiento farmacológico , Transportador de Glucosa de Tipo 4/efectos de los fármacos , Transportador de Glucosa de Tipo 4/metabolismo , Hipoglucemiantes/aislamiento & purificación , Hígado/metabolismo , Hígado/patología , Cromatografía de Gases y Espectrometría de Masas
2.
Biol. Res ; 49: 1-11, 2016. ilus, graf
Artículo en Inglés | LILACS | ID: biblio-950864

RESUMEN

BACKGROUND: From ancient times, marine algae have emerged as alternative medicine and foods, contains the rich source of natural products like proteins, vitamins, and secondary metabolites, especially Chlorella vulgaris (C. vulgaris) contains numerous anti-inflammatory, antioxidants and wound healing substances. Type 2 diabetes mellitus is closely associated with adipogenesis and their factors. Hence, we aimed to investigate the chemical constituents and adipo-genic modulatory properties of C. vulgaris in 3T3-L1 pre-adipocytes. RESULTS: We analysed chemical constituents in ethanolic extract of C. vulgaris (EECV) by LC-MS. Results revealed that the EECV contains few triterpenoids and saponin compounds. Further, the effect of EECV on lipid accumulation along with genes and proteins expressions which are associated with adipogenesis and lipogenesis were evaluated using oil red O staining, qPCR and western blot techniques. The data indicated that that EECV treatment increased differentiation and lipid accumulation in 3T3-L1 cells, which indicates positive regulation of adipogenic and lipogenic activity. These increases were associated with up-regulation of PPAR-γ2, C/EBP-α, adiponectin, FAS, and leptin mRNA and protein expressions. Also, EECV treatments increased the concentration of glycerol releases as compared with control cells. Troglitazone is a PPAR-γ agonist that stimulates the PPAR-y2, adiponectin, and GLUT-4 expressions. Similarly, EECV treatments significantly upregulated PPAR-γ, adiponectin, GLUT-4 expressions and glucose utilization. Further, EECV treatment decreased AMPK-α expression as compared with control and metformin treated cells. CONCLUSION: The present research findings confirmed that the EECV effectively modulates the lipid accumulation and differentiation in 3T3-L1 cells through AMPK-α mediated signalling pathway.


Asunto(s)
Animales , Ratones , Algas Marinas/química , Extractos Vegetales/farmacología , Células 3T3-L1/efectos de los fármacos , Chlorella vulgaris/química , Factores de Tiempo , Regulación hacia Abajo , Expresión Génica , Diferenciación Celular/efectos de los fármacos , Regulación hacia Arriba , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Adipocitos/citología , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células 3T3-L1/fisiología , PPAR gamma/análisis , PPAR gamma/efectos de los fármacos , PPAR gamma/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Adiponectina/análisis , Adiponectina/metabolismo , Transportador de Glucosa de Tipo 4/análisis , Transportador de Glucosa de Tipo 4/efectos de los fármacos , Transportador de Glucosa de Tipo 4/metabolismo , Proteínas Quinasas Activadas por AMP/análisis , Proteínas Quinasas Activadas por AMP/efectos de los fármacos , Proteínas Quinasas Activadas por AMP/metabolismo , Glucosa/metabolismo
3.
Braz. j. med. biol. res ; 49(5): e5129, 2016. tab, graf
Artículo en Inglés | LILACS | ID: biblio-951677

RESUMEN

This study aimed to evaluate the effects of exercise training on triglyceride deposition and the expression of musclin and glucose transporter 4 (GLUT4) in a rat model of insulin resistance. Thirty male Sprague-Dawley rats (8 weeks old, weight 160±10 g) were fed a high-fat diet (40% calories from fat) and randomly divided into high-fat control group and swimming intervention group. Rats fed with standard food served as normal control. We found that 8-week swimming intervention significantly decreased body weight (from 516.23±46.27 to 455.43±32.55 g) and visceral fat content (from 39.36±2.50 to 33.02±2.24 g) but increased insulin sensitivity index of the rats fed with a high-fat diet. Moreover, swimming intervention improved serum levels of TG (from 1.40±0.83 to 0.58±0.26 mmol/L) and free fatty acids (from 837.80±164.25 to 556.38±144.77 μEq/L) as well as muscle triglycerides deposition (from 0.55±0.06 to 0.45±0.02 mmol/g) in rats fed a high-fat diet. Compared with rats fed a standard food, musclin expression was significantly elevated, while GLUT4 expression was decreased in the muscles of rats fed a high-fat diet. In sharp contrast, swimming intervention significantly reduced the expression of musclin and increased the expression of GLUT4 in the muscles of rats fed a high-fat diet. In conclusion, increased musclin expression may be associated with insulin resistance in skeletal muscle, and exercise training improves lipid metabolism and insulin sensitivity probably by upregulating GLUT4 and downregulating musclin.


Asunto(s)
Animales , Masculino , Ratas , Resistencia a la Insulina/genética , Grasas de la Dieta/administración & dosificación , Transportador de Glucosa de Tipo 4/metabolismo , Metabolismo de los Lípidos/genética , Proteínas Musculares/metabolismo , Condicionamiento Físico Animal , Factores de Tiempo , Factores de Transcripción , Resistencia a la Insulina/fisiología , Grasas de la Dieta/metabolismo , Distribución Aleatoria , Regulación de la Expresión Génica , Ratas Sprague-Dawley , Transportador de Glucosa de Tipo 4/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Proteínas Musculares/genética
4.
Indian J Exp Biol ; 2013 Feb; 51(2): 129-138
Artículo en Inglés | IMSEAR | ID: sea-147576

RESUMEN

This study investigates if glycyrrhizin, a constituent of licorice (Glycyrrhiza glabra) root, is able to treat the complications (insulin resistance, hyperglycemia, dyslipidemia and oxidative stress) of metabolic syndrome. Metabolic syndrome was induced in rats by feeding a fructose-enriched (60%) diet for six weeks, after which single dose of glycyrrhizin (50 mg/kg body weight) was administered intraperitoneally. Different biochemical parameters from blood were estimated during three weeks after treatment. Then the rats were sacrificed to collect skeletal muscle tissue. Glycyrrhizin reduced the enhanced levels of blood glucose, insulin and lipids in metabolic syndrome group. Increased advanced glycation end products of hemoglobin, glycohemoglobin, hemoglobin-mediated iron release and iron-mediated free radical reactions (arachidonic acid and deoxyribose degradation) in metabolic syndrome were inhibited by glycyrrhizin treatment. Reduced activities of enzymatic antioxidants (superoxide dismutase and catalase) and elevated oxidative stress markers (malonaldehyde, fructosamine, hemoglobin carbonyl content and DNA damage) in metabolic syndrome were reversed to almost normal levels by glycyrrhizin. The decreased levels of peroxisome proliferator activated receptor (PPAR) and glucose transporter 4 (GLUT4) proteins in skeletal muscle of metabolic syndrome group were elevated by glycyrrhizin, indicating improved fatty acid oxidation and glucose homeostasis.


Asunto(s)
Animales , Biomarcadores/sangre , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Daño del ADN , Dieta , Modelos Animales de Enfermedad , Dislipidemias/sangre , Dislipidemias/complicaciones , Dislipidemias/tratamiento farmacológico , Depuradores de Radicales Libres/metabolismo , Fructosa/efectos adversos , Transportador de Glucosa de Tipo 4/metabolismo , Ácido Glicirrínico/farmacología , Ácido Glicirrínico/uso terapéutico , Hemoglobinas/metabolismo , Hiperglucemia/sangre , Hiperglucemia/complicaciones , Hiperglucemia/tratamiento farmacológico , Insulina/sangre , Resistencia a la Insulina , Lípidos/sangre , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/inducido químicamente , Síndrome Metabólico/complicaciones , Síndrome Metabólico/tratamiento farmacológico , Músculos/efectos de los fármacos , Músculos/metabolismo , Estrés Oxidativo/efectos de los fármacos , PPAR gamma/metabolismo , Ratas , Ratas Wistar , Extractos de Tejidos
5.
Yonsei Medical Journal ; : 1008-1016, 2008.
Artículo en Inglés | WPRIM | ID: wpr-126736

RESUMEN

PURPOSE: Effect of recombinant human growth hormone (rhGH) administration on lipid storage, and its subsequent effect on insulin sensitivity have not yet been adequately examined. Thus, we investigated the effects of rhGH treatment on muscle triglyceride (TG) and ceramide content, and insulin sensitivity after 4 weeks of rhGH administration in rats. MATERIALS AND METHODS: Fourteen rats were randomly assigned to two groups: rhGH injection group (GH, n = 7) and saline injection group (CON, n = 7). GH received rhGH by subcutaneous injections (130microgram/kg(-1)/day(-1), 6 days/week(-1)) for 4 weeks, while CON received saline injections that were equivalent in volume to GH group. Intramuscular TG and ceramide content and hepatic TG content were measured. To determine insulin sesitivity, oral glucose tolerance test (OGTT) and muscle incubation for glucose transport rate were performed in rats, and used as indicators of insulin sensitivity. We also examined plasm lipid profiles. RESULTS: After 4 weeks of rhGH treatment, the GH group had higher muscle and liver TG contents than the CON (p < 0.05). Ceramide content in GH was significantly greater than that in CON (p < 0.05). GH also had higher plasma levels of FFA (p < 0.05), glucose and insulin responses during OGTT (p < 0.05), and lower glucose transport rates in submaximal insulin concentration (p < 0.05) as compared with CON. Results indicate that rhGH treatment is associated with insulin resistance in rats. CONCLUSION: rhGH treatment elevated muscle TG and ceramide content, and hepatic TG content. Thus, elevation of these compounde by rhGH treatment could contribute to the development of insulin resistance in rats.


Asunto(s)
Animales , Humanos , Masculino , Ratas , Ceramidas/metabolismo , Glucosa/metabolismo , Transportador de Glucosa de Tipo 4/metabolismo , Hormona de Crecimiento Humana/administración & dosificación , Resistencia a la Insulina , Músculo Esquelético/efectos de los fármacos , Ratas Sprague-Dawley , Proteínas Recombinantes/administración & dosificación , Triglicéridos/metabolismo
6.
Experimental & Molecular Medicine ; : 535-543, 2007.
Artículo en Inglés | WPRIM | ID: wpr-174049

RESUMEN

Insufficient intracellular fat oxidation is an important contributor to aging-related insulin resistance, while the precise mechanism underlying is unclear. AMP-activated protein kinase (AMPK) is an important regulator of intracellular fat oxidation and was evidenced to play a key role in high-glucose and high-fat induced glucose intolerance. In the present study, we investigated whether altered AMPK expression or activity was also involved in aging-related insulin resistance. Insulin sensitivity of rats' skeletal muscles was evaluated using in-vitro glucose uptake assay. Activity of alpha subunit of AMPK (AMPKalpha) was evaluated by measuring the phosphorylation of both AMPKalpha (P-AMPKalpha) and acetyl-CoA carboxylase (P-ACC), while expression of AMPKalpha was assessed by determining the mRNA levels of AMPKalpha1 and AMPKalpha2, and protein contents of AMPKalpha. Compared with 4-month old rats, 24-month old rats exhibited obviously impaired insulin sensitivity. At the same time, AMPKalpha activity significantly decreased, while AMPKalpha expression did not alter during aging. Glucose transporter 4 expression also decreased in old rats. Compared with 24-month old rats, administration of the specific activator of AMPK, 5-aminoimidazole-4-carboxamide riboside (AICAR), significantly elevated AMPKalpha activity and GluT4 expression. Also, aging-related insulin resistance was significantly ameliorated by AICAR treatment. In conclusion, aging-related insulin resistance is associated with impaired AMPKalpha activity and could be ameliorated by AICAR, thus indicating a possible role of AMPK in aging-induced insulin resistance.


Asunto(s)
Animales , Masculino , Ratas , Proteínas Quinasas Activadas por AMP , Acetil-CoA Carboxilasa/metabolismo , Envejecimiento/fisiología , Aminoimidazol Carboxamida/análogos & derivados , Glucosa/metabolismo , Transportador de Glucosa de Tipo 4/metabolismo , Insulina/sangre , Resistencia a la Insulina , Complejos Multienzimáticos/antagonistas & inhibidores , Músculo Esquelético/metabolismo , Fosforilación , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Ratas Wistar , Ribonucleótidos/farmacología
7.
Experimental & Molecular Medicine ; : 180-189, 2006.
Artículo en Inglés | WPRIM | ID: wpr-15693

RESUMEN

In adipocytes, insulin stimulates glucose transport primarily by promoting the translocation of GLUT4 to the plasma membrane. Requirements for Ca2+/ calmodulin during insulin-stimulated GLUT4 translocation have been demonstrated; however, the mechanism of action of Ca2+ in this process is unknown. Recently, myosin II, whose function in non-muscle cells is primarily regulated by phosphorylation of its regulatory light chain by the Ca2+/calmodulin-dependent myosin light chain kinase (MLCK), was implicated in insulin-stimulated GLUT4 translocation. The present studies in 3T3- F442A adipocytes demonstrate the novel finding that insulin significantly increases phosphorylation of the myosin II RLC in a Ca2+-dependent manner. In addition, ML-7, a selective inhibitor of MLCK, as well as inhibitors of myosin II, such as blebbistatin and 2,3-butanedione monoxime, block insulin- stimulated GLUT4 translocation and subsequent glucose transport. Our studies suggest that MLCK may be a regulatory target of Ca2+/calmodulin and may play an important role in insulin-stimulated glucose transport in adipocytes.


Asunto(s)
Ratones , Animales , Transporte de Proteínas/efectos de los fármacos , Fosforilación , Naftalenos/farmacología , Quinasa de Cadena Ligera de Miosina/antagonistas & inhibidores , Miosina Tipo II/metabolismo , Insulina/farmacología , Transportador de Glucosa de Tipo 4/metabolismo , Inhibidores Enzimáticos/farmacología , Relación Dosis-Respuesta a Droga , Calmodulina/antagonistas & inhibidores , Azepinas/farmacología , Adipocitos/citología , Células 3T3
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA